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Introduction: To determine the sensitivity and accuracy of endo-
bronchial ultrasound guided transbronchial needle aspiration
(EBUS-TBNA) for clarification of the nature of fluorodeoxyglu-
cose-positron emission tomography (18FDG) positive hilar and/or
mediastinal lymph nodes in patients with (suspected) lung cancer.
Methods: All consecutive patients who had undergone EBUS-
TBNA alone for assessment of abnormal 18FDG-uptake in hilar
and/or mediastinal lymph nodes between January 2005 and August
2007 were reviewed.
Results: One-hundred-nine patients underwent EBUS-TBNA of
127 positron emission tomography positive lymph nodes. Hilar
(station 10 or 11) nodes (N1 or N3) were aspirated in 26 patients and
mediastinal (stations 2, 4, 7) nodes (N2 or N3) in 90 patients. In 7
patients both hilar and mediastinal nodes were sampled. There were
no procedure-related complications. Malignancy was detected in 77
(71%) cases. Thirty-two patients were tumor negative by EBUS-
TBNA; subsequent surgical biopsy in 19 showed malignancy in 7. In
four cases the false negative result was due to sampling error and in
three cases due to detection error. In 13 cases surgical staging was
not performed although long term follow-up in 3 showed no evi-
dence of malignancy. The sensitivity and accuracy of EBUS-TBNA
for malignancy in patients with reference pathology was 91% and
92%, respectively. The negative predictive value was 60%. If the 10
cases for which confirmatory surgical staging was not performed are
assumed to be false negative results, overall sensitivity and accuracy
were 82% and 84%, respectively.
Conclusions: EBUS-TBNA offers an effective accurate, minimally
invasive strategy for evaluating FDG avid hilar and mediastinal
lymph nodes. However, negative findings should be confirmed by
surgical staging.
Key Words: Lung cancer, Endobronchial ultrasound, Positron
emission tomography, Mediastinum, Staging.
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18Fluorodeoxyglucose-positron emission tomography(FDG-PET) is being increasingly used by oncologists,
pulmonologists, and thoracic surgeons to evaluate lung
masses, solitary pulmonary nodules and intrathoracic lymph
nodes. As the availability of this technique becomes more
widespread and the cost per examination decreases, it is
likely that its position in the investigation algorithm will
move forward, possibly even as a first line imaging investi-
gation. Although undoubtedly useful, PET brings with it a
new set of challenges, not least of which, is the necessity to
be able to biopsy positive lymph nodes. A series of studies
have shown that while PET has a high negative predictive
value, it is neither sufficiently sensitive nor specific to differ-
entiate benign from malignant intrathoracic lymph node in-
volvement.1,2 Recent pooled data showed that the sensitivity
and specificity of PET for predicting malignant involvement of
mediastinal lymph nodes were 84% and 89%, respectively.3 The
acceptance that PET positive mediastinal lymph nodes equate to
malignant involvement runs the risk of excluding patients from
potentially curative surgery. As a result several national guide-
line groups advise that 18FDG positive intrathoracic lymph
nodes should be biopsied if it is likely that the result will alter
clinical management.4,5
For many years surgical biopsy - principally cervical
mediastinoscopy - has been regarded as the ‘standard proce-
dure’ for sampling mediastinal lymph nodes. However, these
techniques, require general anesthesia and may require an
overnight stay. While the mediastinal lymph node stations
can be accessed by one or more surgical approaches, access
to hilar nodal stations can be difficult and may require
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thoracoscopy and on occasion a thoracotomy. In recent years
there has been increasing interest in the use of minimally
invasive methods for the evaluation of intrathoracic lymph
nodes. One such technique, endobronchial ultrasound guided
transbronchial needle aspiration (EBUS-TBNA), permits bi-
opsy of both hilar and mediastinal lymph nodes.6–10
Our aim in this study was to assess the sensitivity and
accuracy of EBUS-TBNA for clarification of the nature of
18FDG PET positive hilar and/or mediastinal lymph nodes.
PATIENTS AND METHODS
Inclusion and Exclusion Criteria
We retrospectively reviewed the diagnostic perfor-
mance of EBUS-TBNA for assessment of 18FDG positive
hilar or mediastinal lymph nodes. All consecutive patients, in
each center, who had undergone EBUS-TBNA alone, for the
purposes of diagnosis or staging (or both) between January
2005 and August 2007 were included. Patients who were
undergoing EBUS-TBNA for the purposes of mediastinal
restaging following induction chemotherapy were not eligible
for this study. Each center gave approval for the conduct of
the case note review.
Patients
The cohort consisted of 79 men and 30 women (age
range 22–85 years–median 69 years) referred to Papworth
Hospital, Cambridge, UK (n  43), Ghent University Hos-
pital, Belgium (n  36) and Leiden University Medical
Centre, The Netherlands (n  30). In 50 (46%) cases the
patient was known to have lung cancer and in 59 (54%) cases
the diagnosis was suspected. Of the 109 cases, abnormal FDG
uptake was seen in solitary lymph nodes in 91 (83%) cases
and in 2 or more nodes in 18 cases. In 30 (28%) of the 109
patients, the target lymph nodes were 10 mm in short axis.
18FDG PET
All patients underwent either integrated 18FDG PET-
computed tomography (CT) or 18FDG-PET with side by side
comparison with CT imaging. Although initial imaging was
performed at several different referral centers in each coun-
try, 18FDG-PET protocols were similar. Patients were fasted
for 6 hours before the scan and glucose levels were confirmed
to be 200 mg/dl. Image acquisition began exactly 60 min-
utes after an intravenous injection of 4 MBq/Kg FDG. Pa-
tients were scanned from midskull to midthigh and acquisi-
tion time was 3 minutes at each of 8 to 9 table positions. PET
image data sets were reconstructed iteratively using a row
action maximum likelihood algorithm. 18FDG-PET was con-
sidered positive in hilar or mediastinal nodes if the PET
report stated that there was hypermetabolic activity consistent
with malignant disease (defined as standardized uptake value
2.5).
EBUS-TBNA
All EBUS examinations and TBNA procedures were
performed under local anesthesia and moderate sedation us-
ing a linear array ultrasonic bronchoscope (BF-UC260F-
OL8, Olympus Ltd., Tokyo Japan) as described previously.11
A systematic assessment of all lymph node stations in both
the hilar regions (stations 10R, 10L, 11R, and 11L) and the
mediastinum (stations 2R, 2L, 4R, 4L, and 7)12 was under-
taken in addition to evaluation of the lymph node stations of
interest (i.e., those that had shown 18FDG uptake) (Figure 1).
Lymph nodes were sampled in the order N3 then N2 and then
N1 to prevent up-staging in the event of any cross-contami-
nation between samples. Smears of the aspirates obtained by
EBUS-TBNA were either, air-dried, stained with Diff-
Quik™ and examined by ROSE (Leiden and Ghent) or
collected into CytoLyt and processed in a cytopathology
laboratory (Cambridge).
Surgical Staging Procedures
For patients who underwent mediastinoscopy, a stan-
dard cervical mediastinoscopy was performed under general
anesthesia by a thoracic surgeon experienced in the tech-
nique. The standard of practice involved sampling of the
lymph node stations: 2R, 2L, 4R, 4L, and 7. Video assisted
thoracoscopic surgery (VATS) was performed in a lateral
decubitus with single lung ventilation. One to three ports
were used to permit access to lymph node stations 7, 8, and
9. For those undergoing thoracotomy, a standard posterolat-
eral thoracotomy was performed with systematic hilar and
mediastinal lymph node dissection. All mediastinal nodes
that could be reached were actively sought and completely
removed. For left sided tumors lymph node stations 2L, 4L,
FIGURE 1. A, Positron emission tomogra-
phy-computed tomography (PET-CT) image
showing fluorodeoxyglucose (18FDG) up-
take in lymph nodes in stations 4R and 10R.
B, Corresponding image of lymph nodes
seen using linear endobronchial ultrasound.
The needle can be seen lying within a node.
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5 to 9 were dissected and for right sided tumors lymph node
stations 2R, 4R, 7 to 9 were dissected.
Statistical Analysis
For calculation of sensitivity and accuracy of EBUS-
TBNA, only patients who had a confirmatory surgical staging
investigation in the event of a negative for malignancy
EBUS-TBNA were included. For statistical purposes it was
assumed that positive for malignancy EBUS-TBNA results
were true positive although it is recognized that rarely false
positive results have been reported.11 However, because it
was not the normal clinical practice of the investigators to
confirm positive EBUS-TBNA results by surgical biopsy the
specificity of the technique was taken to be one. For the
purposes of analysis a lymph node was regarded as positive
for malignancy if it was shown to contain tumor as a result of
either an EBUS-TBNA aspirate or by surgical biopsy.
Diagnostic sensitivity ([TP/{TP  FN}]; TP, true pos-
itives; FN, false negatives), specificity ([TN/{TN FP}]; FP,
false positives), positive predictive value (TP/[TP  FP]),
negative predictive value ([TN/TN  FN]), and accuracy
([TP  TN]/n) for EBUS-TBNA were calculated using the
software package SPSS v15.0 (SPSS Inc., Chicago, IL).
RESULTS
One hundred nine patients underwent EBUS evaluation
of 127 lymph nodes. Details of lymph node stations biopsied
are shown in Table 1. Lymph node size ranged from 6 to 30
mm with a median size of 15 mm. The mean number of
TBNA passes per node was 3.2 (range, 1–5).
Breakdown by nodal level biopsied showed that N1 nodes
(lymph node stations 10 or 11) were targeted in 15 (14%)
patients. Level N1 nodes were usually biopsied for diagnostic
purposes rather than staging purposes. Level N2 nodes were
biopsied in 80 (75%) patients and N3 nodes in 21 (19%)
patients. N2 and N3 nodes were biopsied for either diagnostic
and/or staging purposes. Of the N3 nodes assessed, 10 were
contralateral mediastinal nodes (stations 2 or 4) and 11 were
contralateral hilar nodes (stations 10 or 11). In 77 (71%)
patients, a diagnosis of malignancy was obtained which
obviated the need for further surgical biopsy (Figure 2).
TBNA results showed small cell lung cancer in 9 (12%)
cases, adenocarcinoma in 25 (33%), squamous cell carcinoma
in 20 (25%) and non small cell lung cancer (unspecified) in
23 (30%) cases. In 42 (55%) of the 77 cases EBUS-TBNA
provided a primary tissue diagnosis in addition to giving
staging information.
In 32 (29%) patients EBUS or EBUS-TBNA showed
no evidence of malignancy (Figure 2). In 19 patients, further
surgical procedures were undertaken. A cervical mediastinos-
copy or mediastinotomy was performed in 5 cases and VATS
in 4 cases. In 10 patients a thoracotomy was performed
following negative surgical staging procedures. These proce-
dures confirmed a true negative EBUS-TBNA result in 12 of
the 19 cases. All cases were shown to be T1–3 N0 non small
cell lung cancer. The false positive FDG uptake in these
lymph nodes was thought to be infection and/or inflamma-
tion. In seven cases, malignancy was identified by surgical
staging or at thoracotomy indicating that the EBUS-TBNA
result was a false negative. In four cases needle marks/
hematoma suggested that the correct lymph node had been
sampled by EBUS-TBNA but surgical staging discovered
malignancy i.e., these were due to sampling error. In all
cases, subsequent biopsying revealed micrometastatic dis-
ease. In three cases nodes other than those sampled by EBUS
were identified as being malignant. This was therefore due to
detection error.
In the remaining 13 patients (9%) no further staging
investigations were performed. In 3 cases, long term fol-
low-up (12 months) and repeat CT indicated a benign etiol-
ogy (infection) and these were deemed to be true negative
109 patientswith proven or presumed NSCLC and with PET
Positive hilar or mediastinal lymph nodes needing tissue verific
EBUS-TBNA
Malignancy shown by EBUS (n=77) No malignancy shown by EBUS (n=32)
Malignant lesion (n=7)
No surgical confirmation
obtained (n=13)
Benign lesion (n=12)
Surgery (n=19)
ation
FIGURE 2. Flow chart showing patient
outcomes.
TABLE 1. Location of Lymph Node Station Biopsied by
EBUS-TBNA
Right upper paratracheal (2R) 3 Left upper paratracheal (2L) 0
Right lower paratracheal (4R) 66 Left lower paratracheal (4L) 3
Subcarina (7) 29
Right hilar (10R) 11 Left hilar (10L) 5
Right interlobar (11R) 6 Left interlobar (11L) 4
EBUS-TBNA, endobronchial ultrasound guided transbronchial needle aspiration.
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cases for malignancy. In one case no further mediastinal staging
was performed and the patient went on to have neo-adjuvant
chemotherapy. Subsequent mediastinoscopy showed no evi-
dence of mediastinal nodal involvement. The remaining nine
patients were treated with palliative intent (chemotherapy, ra-
diotherapy or active supportive care) for lung cancer on the
grounds that they were too frail or ill to undergo further
surgical staging procedures. Therefore, in these 10 cases it
was not possible to accurately determine the true status of the
EBUS-TBNA negative but PET positive nodes.
Overall, for the 96 cases for which there was definitive
reference pathology, the sensitivity of EBUS-TBNA on a per
patient basis was 91% (95% CI 82–95) and diagnostic accu-
racy was 92%. Specificity was 100% (95% CI 73–100) and
positive predictive value was 100% (95% CI 95–100). The
negative predictive value was 60% (95% CI 36–80). There
was no significant difference in sensitivity for detection of
malignancy between hilar (station 10 and 11) nodes (87%)
and mediastinal (station 2, 4, and 7) nodes (92%). Compar-
ison of data between the different centers showed very similar
sensitivity figures: Cambridge 91%; Leiden 92%, and Ghent
89%. The overall prevalence of malignancy was 77%. If the 10
cases for which it was not possible to conclusively determine the
true status of the EBUS negative but PET positive nodes are all
assumed to be false negative EBUS-TBNA results, the sensitiv-
ity becomes 82% and accuracy 84%.
Analysis of PET positive lymph nodes that measured
10 mm or less showed that 33 lymph nodes were sampled
from 30 patients. Nodal size ranged from 6 to 10 mm with a
median of 8.6 mm. Fourteen patients had nodes that were
shown to contain tumor at EBUS. In 16 cases, no tumor was
found. Further surgical staging investigations or thoracotomy
showed true negative results in six cases, false negative
results in four cases and in the remaining six cases no
standard procedure reference pathology was obtained. Anal-
ysis of the nodes on a per patient basis, for which there was
reference pathology, showed a sensitivity of 77%.
In this series the use of EBUS-TBNA obviated the need
for further surgical staging procedures in 71% of patients.
DISCUSSION
In this study we have shown that EBUS-TBNA is a
sensitive and accurate technique for the characterization of
PET positive hilar and mediastinal lymph nodes. The median
size of nodes in this series was 15 mm and 25% were
subcentimeter i.e., they were reported as normal on CT. Our
findings show that it is feasible to use EBUS to identify and
biopsy small FDG positive nodes under local anesthesia and
moderate sedation as a day case. Similar results were ob-
served in all the participating centers indicating that these
results should be reproducible by the majority of reasonably
experienced operators.
The increasing use of PET for assessment of lymph
nodes brings with it the necessity to be able to biopsy positive
findings as previous studies have shown that the sensitivity
and specificity of PET is not sufficiently high to accurately
determine whether lymph nodes are involved by tumor or
not.2 Until recently mediastinal lymph node sampling has
relied on surgical biopsy techniques such as mediastinoscopy,
anterior mediastinotomy or VATS, depending upon location.
Such techniques entail a general anesthetic and often an
in-patient stay and are relatively expensive. A standard cer-
vical mediastinoscopy allows access to the upper mediasti-
num (lymph node stations 2, 4 and the upper/cranial portion
of station 7) and a VATS procedure permits access to stations
7, 8, and 9. However, neither surgical staging procedure can
access hilar nodal stations 10 and 11.
Historically, access to hilar nodes has often necessi-
tated a thoracotomy and as a result is rarely performed
routinely as a staging procedure. Furthermore, most practi-
tioners of conventional nonultrasound guided TBNA have
been reticent to biopsy these nodal stations due to the prox-
imity of major vessels and the lung parenchyma. Therefore,
contralateral N3 hilar nodes may not always be fully evalu-
ated before thoracotomy. This has lead to futile thoracotomies
being performed. In this study we have shown that using
real-time EBUS guided-TBNA, FDG-positive hilar lymph node
stations 10 and 11 (both N1 and N3) can be identified and
sampled. The utility of EBUS-TBNA in this setting makes it a
valuable tool for both diagnostic (N1) and diagnosis/staging (N2
and N3) purposes. Furthermore, sampling of hilar lymph nodes
may, on occasion, help with assessment of the type of surgical
resection required and determine whether sleeve resection, lo-
bectomy or pneumonectomy is required.
Previous reports using EBUS-TBNA for biopsying
PET positive mediastinal lymph nodes in lung cancer have
shown similar results to our data.10,13 However, our multi-
center data show similar results from each center demonstrat-
ing that this is a reliable technique with reproducible results
that it should be possible to emulate in many centers with
appropriate training.
The only other previous studies describing real-time
ultrasound guided biopsy of PET positive mediastinal lymph
nodes concerned EUS-FNA.14,15 The access afforded by
EBUS is complimentary to that accessible by EUS. While
EBUS allows access to paratracheal, subcarinal, and hilar
nodes, EUS permits access to paraoesophageal regions. The
combination of EBUS and EUS allows access to all medias-
tinal lymph node stations except stations 5 and 6 and offers
the prospect of even greater sensitivity and accuracy for
mediastinal staging.16–18
Although EBUS-TBNA and EUS-FNA have been
shown in a number of studies to have high sensitivity and
accuracy for the detection of metastatic disease, the concern
is often raised that fine needle aspiration sampling may miss
small metastatic tumor deposits in some cases. We examined
the reasons for false negative results (7 cases). We concluded
that in four cases it was due to sampling error (i.e., the
appropriate lymph node was identified but tumor was not
detected on sampling) and in three cases due to detection
error (the PET positive node was not identified correctly).
Sampling error will always be a potential problem if only a
small amount of tumor is present within a node but the risk of
a false negative result can be ameliorated by multiple passes
to different parts of the node (average 3.2 passes per node in
this study). A recent study by Seok Lee et al.19 showed that
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maximum diagnostic values were achieved with three aspi-
rations. Detection error can be minimized with careful exam-
ination of all lymph node stations regardless of FDG uptake.
It is known that low volume disease within a lymph node may
give a false negative PET result. Herth et al.20 have recently
reported that up to 10% of patients staged T1N0 by CT-PET
have unexpected hilar or mediastinal metastases. Therefore, it
is our practice to perform confirmatory surgical staging of
EBUS-TBNA negative for malignancy nodes if clinical sus-
picion exists and it will alter management.
We do recognize several limitations to this study. The
analysis was performed retrospectively although data was
collected prospectively. To avoid selection bias we assessed
all consecutive patients who were referred for EBUS at each
center for evaluation of PET positive mediastinal lymph
nodes. Identification of all appropriate cases was facilitated
by access to the prospective databases that each operator
maintains of all their cases. We noted that the majority of
paratracheal nodes sampled were right sided. In this series
this finding is explained by the fact that all three participating
centers also routinely use EUS which is often used in pref-
erence to EBUS for sampling of left paratracheal nodes. Had
EUS-FNA not been available, the percentage of left paratra-
cheal nodes sampled by EBUS-TBNA would likely have
been higher. With regard to the analysis of results tumor
positive EBUS-TBNA results were not surgically verified as
this was not felt to be ethically acceptable and it was assumed
that there were no false positive results although it is recog-
nized that they can occur.21 As the use of PET becomes more
prevalent, the ability to investigate the mediastinum using a
minimally invasive day case based procedure rather than a
surgical approach requiring in patient care and general anes-
thesia may offer a financial saving for health care systems. In
this study we found that the use of EBUS-TBNA obviated the
need for surgical staging procedures in 71% of cases. Future
studies should concentrate on the health economics and cost
effectiveness of such an approach. In addition to staging,
these technologies often allow primary diagnosis to be made
at the same time. In this series EBUS-TBNA provided a
primary tissue diagnosis in addition to giving staging infor-
mation in 55% of cases. In conclusion, EBUS-TBNA offers
clinicians a sensitive, safe and minimally invasive strategy
for the assessment of FDG avid hilar and mediastinal lymph
nodes. As PET becomes more widespread and commonplace
within investigation algorithms, the necessity to be able to
biopsy intrathoracic lymph nodes quickly and efficiently will
likely lead to techniques such as EBUS and EUS becoming
the new first line investigation. However, the relatively low
negative predictive value indicates that negative results
should be confirmed by surgical biopsy.
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